Detalhe da pesquisa
1.
An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia.
Cancer Immunol Immunother
; 72(1): 39-53, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35699757
2.
Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs.
Cancer Immunol Immunother
; 72(7): 2347-2356, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36939853
3.
Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia.
BMC Cancer
; 23(1): 167, 2023 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36803483
4.
Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides.
Cancer Immunol Immunother
; 70(1): 253-263, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32696072
5.
Identification of mouse helper epitopes for WT1-specific CD4+ T cells.
Cancer Immunol Immunother
; 70(11): 3323-3335, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34272593
6.
A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.
Cancer Immunol Immunother
; 68(2): 331-340, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30430205
7.
WT1 peptide-based immunotherapy for advanced thymic epithelial malignancies.
Int J Cancer
; 142(11): 2375-2382, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29322496
8.
Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide.
Int J Cancer
; 139(6): 1391-401, 2016 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27170523
9.
Co-administration of α-GalCer analog and TLR4 agonist induces robust CD8(+) T-cell responses to PyCS protein and WT-1 antigen and activates memory-like effector NKT cells.
Clin Immunol
; 168: 6-15, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27132023
10.
A Zbtb7a proto-oncogene as a novel target for miR-125a.
Mol Carcinog
; 55(12): 2001-2009, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-26713860
11.
Two distinct effector memory cell populations of WT1 (Wilms' tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients.
Cancer Immunol Immunother
; 64(7): 791-804, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25835542
12.
Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.
Cancer Immunol Immunother
; 64(6): 707-16, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25772149
13.
Development of a dendritic cell-targeting lipopeptide as an immunoadjuvant that inhibits tumor growth without inducing local inflammation.
Int J Cancer
; 135(12): 2847-56, 2014 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24789268
14.
Wilms tumour 1 peptide vaccine as a cure-oriented post-chemotherapy strategy for patients with acute myeloid leukaemia at high risk of relapse.
Br J Haematol
; 182(2): 287-290, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28542830
15.
Functional human Th17 clones with WT1-specific helper activity.
Cancer Immunol Immunother
; 62(4): 801-10, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23275045
16.
WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1.
Cancers (Basel)
; 15(2)2023 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36672344
17.
Biased usage of T cell receptor ß-chain variable region genes of Wilms' tumor gene (WT1)-specific CD8+ T cells in patients with solid tumors and healthy donors.
Cancer Sci
; 103(3): 408-14, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22126448
18.
CD48 as a novel molecular target for antibody therapy in multiple myeloma.
Br J Haematol
; 156(2): 213-24, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22098460
19.
T Cell-Intrinsic Vitamin A Metabolism and Its Signaling Are Targets for Memory T Cell-Based Cancer Immunotherapy.
Front Immunol
; 13: 935465, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35844620
20.
Cellular and Humoral Immune Responses Induced by an HLA Class I-restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer.
J Immunother
; 45(1): 56-66, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34874330